Endologix Reports Results for the Second Quarter 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
RBC Capital Downgrades Endologix (ELGX) to Sector Perform
August 3, 2016 6:45 AM EDTRBC Capital downgraded Endologix (NASDAQ: ELGX) from Outperform to Sector Perform with a price target of $12.00 (from $17.00).
For an analyst ratings summary and ratings history on Endologix click here. For more ratings news on Endologix click here.
Shares of Endologix closed at $13.75 yesterday.
... MoreEndologix (ELGX) Tops Q2 EPS by 7c, Bumps Outlook
August 2, 2016 4:36 PM EDTEndologix (NASDAQ: ELGX) reported Q2 EPS of ($0.13), $0.07 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $51 million versus the consensus estimate of $46.3 million.
John McDermott, Endologix Chairman and Chief Executive Officer, said, We continue to deliver solid revenue growth above expectations and are very pleased with the TriVascular mergerintegration. Our revenue performance in the second quarter was driven by strong growth with Nellix in international markets, including the... More
